[Chloroquine retinopathy: avoidable by individualized daily dosing].
作者信息
Ochsendorf F R, Runne U, Goerz G, Zrenner E
机构信息
Abteilung II, Zentrum der Dermatologie und Venerologie, Universität Frankfurt/Main.
出版信息
Dtsch Med Wochenschr. 1993 Dec 23;118(51-52):1895-8. doi: 10.1055/s-2008-1059529.
PMID:8287780
Abstract
摘要
相似文献
1
[Chloroquine retinopathy: avoidable by individualized daily dosing].[氯喹视网膜病变：可通过个体化每日给药避免]
Dtsch Med Wochenschr. 1993 Dec 23;118(51-52):1895-8. doi: 10.1055/s-2008-1059529.
2
Dose relationships in patients with early chloroquine retinopathy.早期氯喹视网膜病变患者的剂量关系。
J Rheumatol. 1987 Jun;14(3):472-5.
3
An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine.氯喹与羟氯喹疗效及安全性的眼科视角
J Rheumatol. 1999 Sep;26(9):1866-8.
4
[Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs].[氯喹和羟氯喹：重要治疗药物的副作用概况]
Hautarzt. 1991 Mar;42(3):140-6.
5
Antimalarials in the treatment of rheumatoid arthritis.抗疟药在类风湿关节炎治疗中的应用
Mod Treat. 1971 Nov;8(4):769-77.
6
[Chloroquine retinopathy: preventable by monitoring the maximum daily dose].[氯喹视网膜病变：通过监测每日最大剂量可预防]
Hautarzt. 1988 Jun;39(6):341-2.
7
Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients.氯喹和羟氯喹视网膜病变：如何随访受影响的患者。
Ann Ophthalmol. 1991 Aug;23(8):290-1.
8
Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.羟氯喹和氯喹：评估视网膜毒性风险。
J Am Optom Assoc. 1993 Nov;64(11):787-97.
9
The blood-retinal barrier in chloroquine retinopathy.氯喹视网膜病变中的血视网膜屏障
Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1726-31.
10
[The therapy of systemic lupus erythematosus].[系统性红斑狼疮的治疗]
Dtsch Med Wochenschr. 1997 Jul 4;122(27):877.
引用本文的文献
1
Use of antimalarials in dermatology.抗疟药物在皮肤科的应用。
J Dtsch Dermatol Ges. 2010 Oct;8(10):829-44; quiz 845. doi: 10.1111/j.1610-0387.2010.07490.x. Epub 2010 Jul 29.
Zotero 插件